key: cord-0857301-r7ihvt41
authors: Xiong, Xingjiang; Wang, Pengqian; Su, Kelei; Cho, William C.; Xing, Yanwei
title: Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis
date: 2020-07-02
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.105056
sha: f76d550266efca4da3ca1f144780d84d923b74cf
doc_id: 857301
cord_uid: r7ihvt41

Currently, coronavirus disease 2019 (COVID-19), which can lead to severe respiratory failure and death, is now a global pandemic with no specific anti-viral drugs or vaccines. However, It is worth noting that traditional Chinese medicine (TCM), especially Chinese herbal medicine (CHM), has been widely applied in mainland China since outbreak, bringing new hope for the prevention and control of COVID-19. A comprehensive literature searching was conducted in 7 electronic databases from their inception up to June 21, 2020 to evaluate the efficacy and safety of CHM for COVID-19. Eighteen randomized controlled trials (RCTs) involving 2275 patients were enrolled. Most of CHMs were originated from classical Chinese herbal formulas. Liquoric Root (Gancao, Radix Glycyrrhizae), Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae), Forsythia Fruit (Lianqiao, Fructus Forsythiae Suspensae), and Bitter Apricot Seed (Kuxingren, Semen Armeniacae Amarum) were most frequently used Chinese herbs. The most commonly used dosage formulation was decoction. Our meta-analyses found that comparing CHM group and conventional western medicine group, CHM group has improvements in several clinical parameters including lung CT, clinical cure rate, ranging from mild to critical cases, length of hospital stay, total score of clinical symptoms, fever reduction time, symptom score of fever, number of cough reduction cases, symptom score of cough, number of fatigue reduction cases, symptom score of fatigue, disappearing time of fatigue, TCM syndrome, viral nucleic acid testing, and inflammatory biomarkers (C-reactive protein). Besides, no severe adverse effects was identified by CHM. CHM, especially classical Chinese herbal formulas, could be used as potential candidates for COVID-19 in this battle.

Since December 2019, coronavirus disease 2019 has broken out in Wuhan, China [1] . The main symptoms include fever, dry cough, and fatigue, while some patients with myalgia and diarrhea. It can lead to severe respiratory failure,

The selection of studies and data extraction were performed independently by two reviewers (Xiong XJ and Wang PQ) according to the preseted inclusion and exclusion criteria. Detailed information of enrolled study was listed as below: (a) basic characteristics of included studies: title of study, authors' name, publication date, sample size, diagnostic criteria, methodological quality, therapeutic schedule in treatment and control groups, components and dosage of CHM, withdraws, and course of treatment; (b) basic characteristics of included patients: age, gender, ratio of mild to severe cases, baseline data of body temperature, heart rate, respiration, blood pressure, previous medical history, and laboratory examination; (c) both primary and secondary outcome measures; and (d) adverse effects. If detailed information on outcome measure was lacking, the first or correspondence author of original study was contacted by email, fax, and telephone, which were recorded in the article. If no response was obtained from the authors, data was recalculated from the graphs using digital ruler software. Otherwise, it was excluded. If disagreements on data extraction were identified, a third party (Xing YW and William CC) was consulted.

Methodological quality of the included trials was also assessed by 2 reviewers (Xiong XJ and Su KL) independently. According to Cochrane Collaboration's tool [14] , 7 fields of risk of bias (ROB) were evaluated as below: adequate sequence generation, allocation concealment, blinding of participants and personnel, blinding of J o u r n a l P r e -p r o o f outcome assessment, incomplete outcome data, selective reporting, and other bias.

Each field was assessed to be "yes" (low ROB), "no" (high ROB), or "unclear" (unclear ROB).

Review Manager software (RevMan, Version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was utilized to conduct the data analysis of dichotomous and continuous outcome measures, which were extracted from the original studies. Weighted mean difference (WMD) was utilized for data measurement of continuous outcomes, while risk ratio (RR) for dichotomous outcomes. All of them were expressed with a 95% confidence interval (CI). When no statistical heterogeneity was identified (heterogeneity test, P ≥ 0.10, or I 2 ≤ 50%), fixed-effects model was selected, otherwise random-effects model was applied.

Funnel plot was also used to evaluate the publication bias. It was regarded as significant difference when P < 0.05.

The flow chart of literature identification and screening is described in Figure 1 .

In total, 5182 related literatures were derived from the above 7 electronic databases.

After removing duplicate publications, 4393 studies were remained. And then, we excluded 4325 studies as they are not RCT, specially, these include reviews, commentaries, editorials, case reports, case series, experimental researches, data mining articles, and irrelevant to COVID-19 after scanning titles and abstracts.

Furthermore, after reading the rest 68 full papers, we further excluded 50 literatures as follows: participants did not meet the inclusion criteria (n = 31); duplicate publications (n = 1); no control group (n = 15); intervention included other medical therapies (n = 2); no clinical data for extraction (n = 1). Ultimately, 18 eligible RCTs were included [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .

Basic characteristics of enrolled studies and subjects was listed in Table 1 .

Among the 18 included trials, 5 were multi-centered trials [21, 24, 27, 30, 32] and the rest 13 were single-centered trials. All of the 18 studies were conducted in mainland China in 2020. One paper was online published in advance with English language [32] , and the rest were in Chinese [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . There were altogether 2275 patients enrolled in this review, with the sample size ranged from 20 to 517. All the included trials evaluated the effects of CHM combined with CWM compared to CWM alone.

The name, usage, dosage of western medicine used in CHM group should be the same as used in CWM group. There is no trial utilized CHM placebo. Treatment duration J o u r n a l P r e -p r o o f varied from 5 to 15 days. Primary outcome measure was reported in 13 studies [15-19, 21, 22, 24, 26, 28, 30-32] . Death was reported in 4 trials [17, 18, 21, 31] . Clinical cure rate was reported in 7 trials [18, 19, 22, 24, 29, 31, 32] . Ranging between mild and critical cases was reported in 12 trials [15-18, 20, 21, 24, 25, 28, 30-32] . Length of hospital stay was reported in 2 trials [17, 18] . All the included trials reported clinical symptoms. TCM syndrome was evalated in 5 studies [18, 20, 28, 29, 31] . Viral nucleic acid testing was reported in 4 trials [15, 21, 23, 32] . Inflammatory biomarkers were reported in 8 trials, including WBC, NEU, LYM, and CRP [15, 16, 18, 19, 21, 22, 29, 31] . Adverse effects were ported in 10 trials [15, 16, 18-20, 22, 23, 25, 31, 32] .

As shown in Table 2 , the methodological quality of the included studies was evaluated based on the criteria in Cochrane handbook. Detailed information on sequence generation of randomization was reported in 6 trials (6/18, 33.33%) [16, 20, 28, [30] [31] [32] . Specific method of allocation concealment was not described in this review. One trial reported no application of blinding [30] . One trial only reported blinding of assessor [32] . Detailed information regarding blinding of patient, investigator, and assessor was unclear in the rest 16 trials [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 31] . Dropouts were reported in 4 trials (4/18, 22.22%) [15, 16, 20, 21] . J o u r n a l P r e -p r o o f capsule, oral liquid, pill, and injection. The most commonly used dosage formulation was decoction (17/31, 54.84%) , followed by granule (7/31, 22 .58%), injection (4/31, 12 .90%), oral liquid (2/31, 6.45%), capsule (2/31, 6.45%) , and pill (1/31, 3.23%) . The decoction of CHM was orally taken 1 dose every day, with about 400ml in every dose. The administration of CHM in each trial was described in Table 1 and the compositions were summarized in Table 3 .

Thirteen trials assessed the efficacy of CHM on lung CT in this study [15-19, 21, 22, 24, 26, 28, 30-32] . There were 749 patients in CHM group and 653 in CWM group. A significant improvement in lung CT was identified by CHM in this metaanalysis (13 trials, n = 1402; RR = 1.23; 95% CI: 1.15 to 1.32; I 2 = 31%, P < 0.00001; Figure 2a ).

The effect of CHM on death was reported in 4 trials [17, 18, 21, 31] . There were 256 patients in CHM group and 207 in CWM group. Meta-analysis showed no significant difference on death between CHM and CWM (4 trials, n = 463; RR = 0.34; J o u r n a l P r e -p r o o f 95% CI: 0.05 to 2.18; I 2 = 0%, P = 0.26; Figure 2b ).

Clinical cure rate was defined as the following 4 discharge criterion in guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia: a) body temperature returned to normal for more than 3 days, b) respiratory symptoms improved significantly, c) pulmonary imaging showed obvious absorption of inflammation, and d) two consecutive times of novel coronavirus nucleic acid test negative in respiratory tract (the sampling interval shall be at least 1 day) [7] . Seven trials evaluated the effects of CHM on clinical cure rate [18, 19, 22, 24, 29, 31, 32] . There were 760 patients in CHM group and 763 in CWM group.

CHM exhibited a significant improvement on clinical cure rate (7 trials, n = 1523; RR = 1.18; 95% CI: 1.13 to 1.24; I 2 = 24%, P < 0.00001; Figure 2c ).

Twelve trials evaluated the effects of CHM on ranging between mild and critical cases [15-18, 20, 21, 24, 25, 28, 30-32] . Among them, effects of CHM on ranging from critical to mild cases were evaluated in 2 trials [16, 17] . There were 100 patients in CHM group and 67 in CWM group. Compared with CWM, no significant difference on ranging from critical to mild cases was identified (RR = 1.34; 95% CI: J o u r n a l P r e -p r o o f 0.47 to 3.80; I 2 = 0%, P = 0.58; Figure 3a ).

In addition, effects of CHM on ranging from mild to critical cases were evaluated in 11 trials [15, 17, 18, 20, 21, 24, 25, 28, [30] [31] [32] . There were 703 patients in CHM group and 543 in CWM group. A significant improvement on ranging from mild to critical cases was observed by CHM (11 trials, n = 1246; RR = 0.40; 95% CI: 0.29 to 0.56; I 2 = 0%, P < 0.00001; Figure 3b ).

Two trials evaluating length of hospital stay were included for further analysis [17, 18] . There were 83 patients in CHM group and 36 in CWM group. Meta-analysis showed a significant reduction on length of hospital stay by CHM (2 trials, n = 119; WMD: -1.99; 95% CI: -3.28 to -0.70; I 2 = 0%, P = 0.002; Figure 3c ).

Clinical symptoms including fever, dry cough, expectoration, fatigue, sore throat, itchy throat, chest tightness, asthma, shortness of breath, poor appetite, diarrhea, nausea, vomiting, abdominal distention, and abdominal pain were reported in all the included studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . As fever, dry cough, and fatigue were main clinical symptoms of COVID-19, individual symptom score, disappearing time, number of improved cases, and total score of clinical symptom were summarized. Total score of clinical symptom was evaluated in 2 studies [15, 17] . There were 101 patients in CHM group and 32 in CWM group. Meta-analysis revealed a significant improvement on total score of clinical symptom (2 trials, n = 133; WMD: -1.84; 95% CI: -3.10 to -0.58; I 2 = 0%, P = 0.004; Figure 4a ).

The symptom of fever was reported in 15 trials [15-25, 27, 28-30, 32] . Among them, 5 studies reported number of fever reduction cases [15, 16, 20, 27, 30] , 10 reported fever reduction time [17, 18, 21-25, 27, 28, 32] , and 3 reported symptom score of fever [19, 29, 31] .

In the field of number of fever reduction cases, there were 238 patients in CHM group and 150 in CWM group. Meta-analysis revealed no significant difference on fever reduction number between CHM and CWM (5 trials, n = 388; RR = 1.28; 95% CI: 0.98 to 1.67; I 2 = 66%, P = 0.07; Figure 4b ).

In the field of fever reduction time, there were 551 patients in CHM group and 466 in CWM group. The aggregated results including 10 trials suggested that fever reduction time is significantly improved by CHM (10 trials, n = 1017; WMD: -1.36; 95% CI: -1.80 to -0.93; I 2 = 58%, P < 0.00001; Figure 4c ).

In the field of symptom score of fever, there were 433 patients in CHM group and 452 in CWM group. It has been identified that score of fever is significantly J o u r n a l P r e -p r o o f 20 reduced by CHM (3 trials, n = 885; WMD: -0.60; 95% CI: -0.69 to -0.50; I 2 = 61%, P < 0.00001; Figure 4d ).

The symptom of cough was reported in all the trials, and only 14 were enrolled in this review [16, [19] [20] [21] [22] [23] [24] [25] [27] [28] [29] [30] [31] [32] . Among them, 6 studies reported number of cough reduction cases [16, 20, 24, 25, 27, 30] , 4 reported symptom score of cough [19, 21, 29, 31] , and 6 reported disappearing time of cough [22-24, 28, 30, 32] .

In the field of number of cough reduction cases, there were 240 patients in CHM group and 182 in CWM group. Meta-analysis showed a significant improvement on number of cough reduction cases by CHM (6 trials, n = 422; RR = 1.50; 95% CI: 1.26 to 1.78; I 2 = 0%, P < 0.00001; Figure 5a ).

In the field of symptom score of cough, there were 459 patients in CHM group and 475 in CWM group. The aggregated results suggested that cough is significantly improved by CHM (4 trials, n = 934; WMD: -0.78; 95% CI: -1.32 to -0.24; I 2 = 99%, P = 0.004; Figure 5b ).

In the field of disappearing time of cough, there were 362 patients in CHM group and 336 in CWM group. No significant difference on disappearing time of cough between CHM and CWM was identified in this study (6 trials, n = 698; WMD: -1.42; 95% CI: -2.82 to -0.01; I 2 = 90%, P = 0.05; Figure 5c ).

The effect of CHM on fatigue was evaluated in 12 studies [19-25, 27, 29-32] .

Among them, 5 studies reported number of fatigue reduction cases [20, 24, 25, 27, 30] , 4 reported individual symptom score [19, 21, 29, 31] , and 4 reported disappearing time of fatigue [22] [23] [24] 32] . to -0.04; I 2 = 93%, P = 0.04; Figure 6c ).

The efficacy of CHM on TCM syndrome was evalated in 5 studies [18, 20, 28, J o u r n a l P r e -p r o o f 29, 31] . Only 3 trials could be enrolled in this study. There were 141 patients in CHM group and 84 in CWM group. Meta-analysis showed significant improvement by CHM on TCM syndrome (3 trials, n = 225; WMD: -3.67; 95% CI: -6.60 to -0.73; I 2 = 86%, P = 0.01; Figure 7a ).

The effect of CHM on viral nucleic acid testing was reported in 4 trials [15, 21, 23, 32] . There were 260 patients in CHM group and 209 in CWM group. A significant improvement on negative conversion rate of viral nucleic acid testing was identified by CHM when compared with CWM (4 trials, n = 469; RR = 1.18; 95% CI: 1.04 to 1.34; I 2 = 41%, P = 0.01; Figure 7b ). Additionally, the negative conversion time of viral nucleic acid testing was reported in 1 trial [23], and a shorter time was identified in CHM group (9.32±3.03 vs 11.89±3.21).

Six trials evaluated the efficacy of CHM on number of WBC [15, 18, 19, 22, 29, 31] . As enumeration data was used in 1 trial [18] , 5 trials were included in this study [15, 19, 22, 29, 31] . There were 585 patients in CHM group and 566 in CWM group.

Meta-analysis showed no significant difference between CHM and CWM on the number of WBC in patients with COVID-19 (5 trials, n = 1151; WMD: 0.27; 95% CI: -0.22 to 0.76; I 2 = 95%, P = 0.28; Figure 7c ).

For the number of NEU, 3 trials [15, 18, 21] involving 167 patients were enrolled. As enumeration data and percentage were used in 2 trials [15, 21] , metaanalysis could not be conducted accordingly. Among them, a significant improvement of NEU was identified in 1 trial [18] (P < 0.05), while negative conclusions were found in the rest 2 trials [15, 21] .

Effects of CHM on the level of LYM were assessed in 6 trials [15, 18, 19, 21, 22, 31] . As enumeration data and percentage were reported in 2 trials with positive conclusions [19, 22] , only 4 trials were included in this meta-analysis. Meta-analysis revealed no significant difference between CHM and CWM on the level of LYM (4 trials, n = 483; WMD: 0.24; 95% CI: -0.04 to 0.51; I 2 = 97%, P = 0.09; Figure 7d ).

The levels of CRP at baseline and after intervention were recorded in 7 trials [15, 16, 18, 19, 21, 29, 31] . Although positive conclusion was identified in 1 trial [19] , it could not be included in the meta-analysis due to enumeration data. Meta-analysis of the rest 6 trials revealed that CRP is significantly reduced by CHM (6 trials, n = 1100; WMD: -8.91; 95% CI: -12.56 to -5.27; I 2 = 97%, P < 0.00001; Figure 7e ).

In this review, 10 trials reported adverse effects (10/18, 55 .56%) [15, 16, 18-20, 22, 23, 25, 31, 32] . Among them, no adverse effect was identified in both CHM and CWM groups [18, 19, 25, 31] . Adverse effects in the rest 6 trials included gastrointestinal reactions (abdominal distention, diarrhea, abdominal pain, nausea, vomiting, belching, acid reflux, poor appetite), headache, dizziness, drowsiness, abnormal liver function, renal dysfunction, and drug allergy [15, 16, 20, 22, 23, 32] .

All of the reported adverse effects were released spontaneously in both CHM and CWM groups. Meta-analysis identified that no significant difference between CHM and CWM was identified (9 trials, n = 1069; RR = 0.93; 95% CI: 0.49 to 1.75; I 2 = 46%, P = 0.82; Figure 8 ).

Publication bias was detected by the funnel plot of lung CT. The asymmetry J o u r n a l P r e -p r o o f suggested a mild publication bias in the study (Figure 9 ).

Currently, COVID-19 has become a major public health problem in the whole world [33, 34] . It has been identified that clusters of fatal pneumonia could be caused by 2019 novel coronavirus (2019-nCoV), the clinical manifestation of which is greatly resembling severe acute respiratory syndrome coronavirus (SARS-CoV) [35] .

During the epidemic, rapid and robust research is important to help guide clinical treatment, formulating public health policy, and new drug research and development. than disease were focused accordingly [36] . When in treating acute infectious febrile diseases, large quantity of classical Chinese herbal formulas have been formed and accumulated in ancient times [37] . It is held that COVID-19 belong to "damp-heat epidemic" or "damp-toxin epidemic" according to TCM theory. The disease can be J o u r n a l P r e -p r o o f divided into 3 stages on the basis of different TCM pathogenesis: illness in all three yang channels in the mild stage, phlegm-heat obstructing the lung in the critical stage, and deficiency of lung and spleen qi in the recovery stage. Therefore, therapeutic principles of dispelling cold, relieving exterior, dissipating phlegm, clearing away heat, invigorating spleen, and replenishing qi were widely used. Classical Chinese herbal formulas including Maxing Shigan decoction, Xiaochaihu decoction, etc. were frequently applied correspondingly. What's more, all these formulas possessed a wide range of pharmacological functions including anti-inflammatory, antiviral, antipyretic, expectorant, antiasthmatic, antitussive effects [38] . However, more researches on clinical evidence and molecular mechanism by classical Chinese herbal formulas are also warranted.

Thirdly, treatment course of CHM was also worthy of attention. The reported course ranged from 5 to 15 days. Whether CHM can play a role in such a short period of time is a widely concerned issue. Patients diagnosed as COVID-19 could develop severe pulmonary infection and acute respiratory distress syndrome, which have a high likelihood of hospitalization in intensive care unit and death. However, TCM often held that "to treat what and when it is not ill". That is to say, although patient manifested fever in the early stage and mild stage of COVID-19, it belongs to the category of typical exterior syndrome from the perspective of TCM. If it was intervened in time at the stage of exterior syndrome, COVID-19 can be effectively blocked in ranging from mild to critical cases, thus reducing mortality, length of hospital stay, and fever reduction time.

Fourthly, in terms of adverse effects, no severe discomfort and abnormal liver and kidney function was identified in CHM group. The results indicated that CHM maybe relatively safe for COVID-19. However, as adverse effects were not reported in some studies, the safety of CHM should be observed and reported in more detailed information.

Fifthly, the most frequently used Chinese herbs were also analysed in this study.

In the top 5 herbs, Liquoric Root (Gancao, Radix Glycyrrhizae) is traditionally used as "Shi" to harmonize the properties of different drugs. It is also widely used to resolve phlegm and relieve cough. Glycyrrhetinic acid (Fig 10a) , the effective E.coli, staphylococcus aureus, salmonella typhi, escherichia coli, multidrug-resistant acinetobacter baumannii, and staphylococcus epidermidis [39] . Bitter Apricot Seed (Kuxingren, Semen Armeniacae Amarum) could be used to reduce qi, relieve cough and asthma, and relax bowel, thus treating cough, asthma, chest fullness, phlegm, and constipation. The main active ingredient is amygdalin (Fig 10e) , which possesses the effects of expectorant and antitussive. It is noteworthy that, oxidative stress is a negative effect produced by free radicals in the body, and is considered to be an important factor leading to apoptosis, aging and disease [40] [41] [42] [43] . Virus infection is closely related to oxidative injury, and it evokes oxidative stress and intensifies pathological process. Plant polyphenols include flavonoids, tannins, phenolic acids, etc., which have the functions of scavenging free radicals in the body, anti lipid oxidation, delaying the aging of the body, and possess the effects of bacteriostasis, anti-virus, and anti-tumor [44] . 

Limitations in this review should also be taken into account as below. Firstly, poor methodological design is a very common problem in most of included trials.

Significant drawbacks regarding sequence generation of randomization, concealment of allocation, reporting on blinding, dropouts, and pre-estimation of sample size should be considered in further studies. Secondly, as viral nucleic acid testing turning positive again is very common in the recovery stage of COVID-19, no trial adopted long-term follow-up.

In general, this systematic review and meta-analysis suggested that CHM maybe beneficial for the treatment of COVID-19 in improving clinical symptoms, imaging, and laboratory indicators, shortening the course of disease, and reducing the number of severe cases. However, considering the shortcomings of original trials, further rigorously designed trials following CONSORT Statement [45] and CONSORT extension for herbal medicine [46] are warranted to confirm the conclusions. CHM, especially classical Chinese herbal formulas, could be used as potential candidates for 

A novel coronavirus from patients with pneumonia in China

Oseltamivir compared with the Chinese traditional therapy Maxingshigan-Yinqiaosan in the treatment of H1N1 influenza: A randomized trial

Current situation and perspectives of clinical study in integrative medicine in China. Evid Based Complement Alternat Med

SARS: Clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective

The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence

The efficacy of Lianhua Qingwen combined with western medicine scheme on COVID-19 general type patients: a systematic review

Clinical effects of integrated traditional Chinese and western medicine on COVID-19: a systematic review

The curative effect on treating COVID-19 by integrated medicine: a systematic review

Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of randomized controlled trials

Preferred Reporting Items for Systematic Reviews and meta-analyses: the PRISMA statement

Efficacy and safety of Chinese herbal medicine for patients with postmenopausal hypertension: a systematic review and meta-analysis

Treatment of COVID-19 by pneumonia No.1 prescription and pneumonia No.2 prescription

Clinical effect and mechanism of Qingfei Touxie Fuzheng recipe in the treatment of novel coronavirus pneumonia

Clinical observation on 49 cases of non-critical coronavirus disease 2019 in Shanghai treated by integrative traditional Chinese and western medicine

Clinical study on 34 novel coronavirus pneumoniae treated with integrated traditional Chinese and western medicine

Clinical study on 37 case of COVID-19 treated with integrated traditional Chinese and western medicine

Corona Virus Disease

Study on clinical efficacy of Lianhua Qingke Granule in treatment of mild and ordinary COVID-19

Clinical efficacy of Lianhua Qingwen granule combined with abidol in treating coronavirus disease 2019

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial

Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia

Can traditional Chinese medicine be used for prevention of Corona Virus Disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs

A novel coronavirus associated with severe acute respiratory syndrome

Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine

Evidencebased TAM classic herbal formula: from myth to science. Evid Based Complement Alternat Med

Uncovering the mechanism of Maxing ganshi decoction on asthma from a systematic perspective: a network pharmacology study

Study on the pharmacological action of antibacterial and antiviral by Forsythia Fruit (Lianqiao, Fructus Forsythiae Suspensae)

Poor cognitive ageing: vulnerabilities, mechanisms and the impact of nutritional interventions

Hericium erinaceus prevents DEHP-induced mitochondrial dysfunction and apoptosis in PC12 cells

GABA-containing Compound gammapyrone protects against brain impairments in Alzheimer's disease model male rats and prevents mitochondrial dysfunction in cell culture

Protective actions of anserine under diabetic conditions

Healthy effects of plant polyphenols: molecular mechanisms

statement: updated guidelines for reporting parallel group randomized trials

Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement

Radix Scutellariae Baicalensis) 10g, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 10g, Codonopsis Root (Dangshen, Radix Codonopsitis Pilosulae) 15g, Snakegourd fruit (Gualou, Fructus Trichosanthis) 10g, Areca Seed (Binglang, Semen Arecae) 10g, Fruit of Caoguo (Caoguo, Fructus Tsaoko) 15g, Magnolia Bark (Houpu, Cortex Magnoliae Officinalis) 15g, Anemarrhena Rhizome (Zhimu, Rhizoma Anemarrhenae Aspheloidis) 10g, White Peony Root (Baishaoyao

formula: Ephedra (Mahuang, Herba Ephedrae) 10g, Bitter Apricot Seed (Kuxingren, Semen Armeniacae Amarum) 10g, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 10g, Immature Bitter Orange (Zhishi, Fructus Citri Seu Ponciri Immaturus) 20g, Snakegourd fruit (Gualou, Fructus Trichosanthis) 10g, Coptis Rhizome (Huanglian, Rhizoma Coptidis) 10g, Thunberbg Fritillary Bulb (Zhebeimu, Bulbus Fritillariae Thunbergii) 20g, Root of the Balloon Flower (Jiegeng, Platycodi Radix) 10g, Stemona Root (Baibu, Radix Stemonae) 10g, Hogfennel Root (Qianhu, Radix Peucedani) 10g, Honey-fried Tatarian Aster Root (Ziwan, Radix Asteris Tatarici) 10g, Common Coltsfoot Flower (Kuandonghua, Flos Farfarae) 10g, Climbing Nightshade (Baiying, Herba Solani) 20g, Atrina Glass (Baijiangcao, Herba Patriniae) 15g, Mongolian Dandelion Herb (Pugongying, Herba Taraxaci)15g, and Tokyo Violet Herb (Zihuadiding, Herba Violae) 15g

Fructus Forsythiae Suspensae) 15g, Reed rhizome (Lugen, Rhizoma Phragmitis) 30g, Coix seed (Yiyiren, Semen Coicis) 30g, Body of sick Silkworm (Jiangcan, Bombyx Batryticatus) 10g, Circada Moulting (Chantui, Periostracum Cicadae) 10g, Giant Knotweed Rhizome (Huzhang, Rhizoma Polygoni Cuspidati) 15g, Turmeric (Jianghuang, Rhizoma Curcumae Longae) 10g, White Peony Root (Baishaoyao, Radix Albus Paeoniae Lactiflorae) 10g, Pseudostellaria Root (Taizishen, Pseudostellariae Radix) 20g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 15g. If dampness is severe

Radix Bupleuri) were added. If cough and phlegm were identified, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) and Tendrilleaf Fritillary Bulb (Chuanbeimu, Bulbus Fritillariae Cirrhosae) were added. If chest tightness was identifed

European Verbena Herb (Mabiancao, Herba Verbenae

Indigowoad Root (Banlangen, Radix Isatidis), Male fern rhizome (Mianma Guanzhong, Rhizoma Dryopteris Crassirhizomae), Heartleaf houttuynia herb (Yuxingcao, Herba Houttuyniae), Cablin patchouli herb (Huoxiang, Herba Pogostemonis), Rhubarb Root and Rhizome (Dahuang

Root of the Balloon Flower (Jiegeng, Platycodi Radix)

Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), and Forsythia Fruit (Lianqiao, Fructus Forsythiae Suspensae)

Yupingfeng granules ▲ : Astragalus (Huangqi, Radix Astragali Membranacei), White Atractylodes Rhizome (Baizhu, Rhizoma Atractylodis Macrocephalae), and Ledebouriella Root (Fangfeng, Radix Ledebouriellae Divaricatae)

Rhizoma Atractylodis) 30g, Dahurian Angelica Root (Baizhi, Radix Angelicae Dahuricae) 10g, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15g, Cablin patchouli herb (Huoxiang, Herba Pogostemonis) 15g, Poria (Fuling, Scierotium Poriae Cocos) 30g, Ephedra (Mahuang, Herba Ephedrae) 9g, Rhubarb Root and Rhizome (Dahuang, Radix Et Rhizoma Rhei) 10g

Fructus Trichosanthis) 30g, Rhubarb Root and Rhizome (Dahuang, Radix Et Rhizoma Rhei) 6g, Ephedra (Mahuang, Herba Ephedrae) 6g, Ephedra (Mahuang, Herba Ephedrae) 6g, Pepperweed seed (Tinglizi, Semen Lepidii) 10g, Peach Kernel (Taoren, Persicae Semen) 10g, Fruit of Caoguo (Caoguo, Fructus Tsaoko) 6g, Areca Seed (Binglang, Semen Arecae) 10g

Artemisiae Capillaris Herba) 10g, Cablin patchouli herb (Huoxiang, Herba Pogostemonis) 6g, Forsythia Fruit (Lianqiao, Fructus Forsythiae Suspensae) 10g, Acorus Root (Shichangpu, Acori Rhizoma) 6g, Cardamon Fruit (Baidoukou, Fructus Ammomi Rotundus) 6g, Field Mint (Bohe, Herba Menthae Haplocalycis) 6g, Ricepaperplant Pith (Tongcao

Mangxing Shigan decoction ▲ : Ephedra (Mahuang, Herba Ephedrae) 6g, Bitter Apricot Seed (Kuxingren, Semen Armeniacae Amarum) 10g, Liquoric Root (Gancao, Radix Glycyrrhizae) 6g, and Gypsum

Radix Scutellariae Baicalensis) 6g, Atractylodes Rhizome (Cangzhu, Rhizoma Atractylodis) 10g, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 10g, Liquoric Root (Gancao, Radix Glycyrrhizae) 6g, White Atractylodes Rhizome (Baizhu

Cortex Magnoliae Officinalis) 10g, Ginseng (Renshen, Radix Ginseng) 10g, Polyporus Sclerotium (Zhuling, Sclerotium Polypori Umbellati) 15g, Alisma (Zexie, Rhizoma Alismatis) 10g, and Cassia twig

Haoqin Qingdan decoction ▲ : Sweet Wormwood (Qinghao, Artemisiae Apiaceae seu Annuae Herba) 6g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10g, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae)10g, Poria (Fuling, Scierotium Poriae Cocos) 10g, Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis) 10g, Orange Fruit (Zhike, Fructus Aurantii) 6g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 6g, Talc (Huashi, Talcum) 20g, Natural Indigo (Qingdai, Indigo Naturalis) 10g, and Liquoric Root

Semen Armeniacae Amarum) 10g, Coix seed (Yiyiren, Semen Coicis) 15g, Cardamon Fruit (Baidoukou, Fructus Ammomi Rotundus) 6g, Polyporus Sclerotium (Zhuling, Sclerotium Polypori Umbellati) 10g, Fermented soybean (Dandouchi, Semen Sojae Preparatum) 10g, Alisma (Zexie, Rhizoma Alismatis) 6g, and Ricepaperplant Pith (Tongcao, Medulla Tetrapanacis) 6g. Qiwei decoction: Thorowax Root (Chaihu, Radix Bupleuri) 6g, Magnolia Bark (Houpu, Cortex Magnoliae Officinalis) 10g, Liquoric Root (Gancao, Radix Glycyrrhizae) 6g, Cinnamon Bark (Rougui

Indigowoad Root (Banlangen, Radix Isatidis), Male fern rhizome (Mianma Guanzhong, Rhizoma Dryopteris Crassirhizomae), Heartleaf houttuynia herb (Yuxingcao, Herba Houttuyniae), Cablin patchouli herb (Huoxiang, Herba Pogostemonis), Rhubarb Root and Rhizome (Dahuang

Liquoric Root (Gancao, Radix Glycyrrhizae), Patchouli oil, Perilla leaf oil, Calculus Bovis Sativus, etc. Xuebijing injection ▲ : Safflower Flower (Honghua, Flos Carthami Tinctorii), Red Peony Root (Chishao, Radix Rubrus Paeoniae Lactiflorae)

Tanreqing injection: Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), Bear bile powder (Xiongdanfen, Ursi Fellis Pulvis), Goat Horn (Shanyangjiao, Saigae Tataricae Cornu), Honeysuckle bud and flower (Jinyinhua, Flos Lonicerae), and Forsythia Fruit (Lianqiao, Fructus Forsythiae Suspensae)

Shengmai injection ▲ : Red ginseng (Hongshen, Radix Ginseng Rubra), Ophiopogon (Maidong, Tuber Ophiopogonis Japonici), and Chinese Magnoliavine Fruit (Wuweizi, Fructus Schisandrae Chinensis)

Shenfu injection ▲ : Red ginseng (Hongshen, Radix Ginseng Rubra), and Processed aconite (Fuzi, Radix Lateralis Praeparatus Aconiti Carmichaeli)

Radix Scutellariae Baicalensis) 10g, Dyers Woad Leaf (Daqingye, Folium Isatidis) 10g

Bitter Apricot Seed (Kuxingren, Semen Armeniacae Amarum)

Giant Knotweed Rhizome (Huzhang, Rhizoma Polygoni Cuspidati), Atrina Glass (Baijiangcao, Herba Patriniae), Barbated Skullcup Herb (Banzhilian, Herba Scutellariae Barbatae)

European Verbena Herb (Mabiancao, Herba Verbenae

European Verbena Herb (Mabiancao, Herba Verbenae

Indigowoad Root (Banlangen, Radix Isatidis), Male fern rhizome (Mianma Guanzhong, Rhizoma Dryopteris Crassirhizomae), Heartleaf houttuynia herb (Yuxingcao, Herba Houttuyniae), Cablin patchouli herb (Huoxiang, Herba Pogostemonis), Rhubarb Root and Rhizome (Dahuang

Lianhua Qingwen granules ▲

Indigowoad Root (Banlangen, Radix Isatidis), Male fern rhizome (Mianma Guanzhong, Rhizoma Dryopteris Crassirhizomae), Heartleaf houttuynia herb (Yuxingcao, Herba Houttuyniae), Cablin patchouli herb (Huoxiang, Herba Pogostemonis), Rhubarb Root and Rhizome (Dahuang

Pericarpium Citri Reticulatae) 6g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 10g, Chinese Date (Dazao, Fructus Zizyphi Jujubae) 6, Fresh Ginger Rhizome (Shengjiang, Fresh Rhizoma Zingiberis) 9 slices

Indigowoad Root (Banlangen, Radix Isatidis), Male fern rhizome (Mianma Guanzhong, Rhizoma Dryopteris Crassirhizomae), Heartleaf houttuynia herb (Yuxingcao, Herba Houttuyniae), Cablin patchouli herb (Huoxiang, Herba Pogostemonis), Rhubarb Root and Rhizome (Dahuang

Herba Ephedrae) 9g, Bitter Apricot Seed (Kuxingren, Semen Armeniacae Amarum) 12g, Gypsum (Shigao, Gypsum Fibrosum) 15-30g, Thunberbg Fritillary Bulb (Zhebeimu, Bulbus Fritillariae Thunbergii) 12g, Circada Moulting (Chantui, Periostracum Cicadae) 10g, Body of sick Silkworm (Jiangcan, Bombyx Batryticatus) 15g, Turmeric (Jianghuang, Rhizoma Curcumae Longae) 12g, Root of the Balloon Flower (Jiegeng, Platycodi Radix) 12g, Orange Fruit (Zhike, Fructus Aurantii) 12g, Fruit of Caoguo (Caoguo, Fructus Tsaoko) 9g, and Cardamon Fruit

Radix Scutellariae Baicalensis) 10g, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 10g, Codonopsis Root (Dangshen, Radix Codonopsitis Pilosulae) 15g, Snakegourd fruit (Gualou, Fructus Trichosanthis) 10g, Areca Seed (Binglang, Semen Arecae) 10g, Fruit of Caoguo (Caoguo, Fructus Tsaoko) 15g, Magnolia Bark (Houpu, Cortex Magnoliae Officinalis) 15g, Anemarrhena Rhizome (Zhimu, Rhizoma Anemarrhenae Aspheloidis) 10g, White Peony Root (Baishaoyao

Rhizoma Pinelliae Tematae) 10g, Areca Seed (Binglang, Semen Arecae) 15g, Fruit of Caoguo (Caoguo, Fructus Tsaoko) 6g, Snakegourd fruit (Gualou, Fructus Trichosanthis) 10g, Liquoric Root (Gancao, Radix Glycyrrhizae) 6g, Giant Knotweed Rhizome (Huzhang

Mulberry Root Bark (Sangbaipi, Mori Radicis Cortex)

Lianhua Qingwen granules ▲

Indigowoad Root (Banlangen, Radix Isatidis), Male fern rhizome (Mianma Guanzhong, Rhizoma Dryopteris Crassirhizomae), Heartleaf houttuynia herb (Yuxingcao, Herba Houttuyniae), Cablin patchouli herb (Huoxiang, Herba Pogostemonis), Rhubarb Root and Rhizome (Dahuang

Lianhua Qingwen capsules ▲

Indigowoad Root (Banlangen, Radix Isatidis), Male fern rhizome (Mianma Guanzhong, Rhizoma Dryopteris Crassirhizomae), Heartleaf houttuynia herb (Yuxingcao, Herba Houttuyniae), Cablin patchouli herb (Huoxiang, Herba Pogostemonis), Rhubarb Root and Rhizome (Dahuang

Abbreviation: CHM: Chinese herbal medicine; ▲ : originated from classical Chinese herbal formulas

The authors declared that there is no conflict of interest.J o u r n a l P r e -p r o o f